Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Assets (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Assets for 15 consecutive years, with $814.9 million as the latest value for Q1 2026.

  • For Q1 2026, Assets fell 3.73% year-over-year to $814.9 million; the TTM value through Mar 2026 reached $814.9 million, down 3.73%, while the annual FY2025 figure was $836.7 million, 0.46% changed from the prior year.
  • Assets hit $814.9 million in Q1 2026 for Corcept Therapeutics, down from $836.7 million in the prior quarter.
  • Across five years, Assets topped out at $846.5 million in Q1 2025 and bottomed at $468.1 million in Q1 2022.
  • Average Assets over 5 years is $679.9 million, with a median of $655.9 million recorded in 2024.
  • On a YoY basis, Assets climbed as much as 37.68% in 2022 and fell as far as 15.26% in 2022.
  • Corcept Therapeutics' Assets stood at $583.4 million in 2022, then rose by 6.53% to $621.5 million in 2023, then soared by 35.24% to $840.6 million in 2024, then fell by 0.46% to $836.7 million in 2025, then fell by 2.6% to $814.9 million in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $814.9 million, $836.7 million, and $823.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.